Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma
Authors:
- Shigeki KusamuraSKShigeki Kusamura
- Dario BarattiDBDario Baratti
- Michele De SimoneMSMichele De Simone
- Enrico Maria PasqualEPEnrico Maria Pasqual
- Luca AnsaloniLALuca Ansaloni
- Daniele MarrelliDaniele Marrelli
- Manuela RobellaMRManuela Robella
- Fabio AccarpioFAFabio Accarpio
- Mario ValleMVMario Valle
- Stefano ScaringiSSStefano Scaringi
- Daniele BiacchiDBDaniele Biacchi
- Carmen PalopoliCPCarmen Palopoli
Open Access
Abstract
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare form of mesothelioma that carries a very poor prognosis. The 5-year overall survival is about 20% (±5.9). Survival is optimal for patients suitable for cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), with a median OS ranging from 34 to 92 months. However, selecting patients for surgery remains a complex task and requires a careful preoperative workup, rational analysis of prognostic profiles, and risk prediction models. Systemic chemotherapy could be offered: (1) in the adjuvant setting for high-risk patients; (2) for patients not eligible for CRS; and (3) for those with recurrent disease. It mainly includes the combination of Platin compound with Pemetrexed or immunotherapy. The biology of DMPM is still largely unknown. However, progress has been made on some fronts, such as telomere maintenance mechanisms, deregulation of apoptosis, tyrosine kinase pathways, and mutation of BRCA1-associated protein 1 (BAP1). Future perspectives should include translational research to improve our understanding of the disease biology to identify druggable targets. We should also clear the role of immune checkpoint inhibitors and investigate new locoregional technologies, such as pressurized intraperitoneal aerosol chemotherapy (PIPAC) or normothermic intraperitoneal chemotherapy (NIPEC).Keywords
Funding Information
- RAND Corporation
- AIRC (Italian Association for Cancer Research)
This publication has 91 references indexed in Scilit:
- Diffuse malignant peritoneal mesothelioma – An update on treatmentCancer Treatment Reviews, 2012
- Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal MesotheliomaGastroenterology Research and Practice, 2012
- Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesotheliomaEuropean Journal of Cancer, 2010
- What are the current barriers to effective cancer care coordination? A qualitative studyBMC Health Services Research, 2010
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Circulating CA125 and diffuse malignant peritoneal mesotheliomaEuropean Journal of Surgical Oncology, 2009
- Malignant peritoneal mesothelioma: a multicenter study on 81 casesAnnals of Oncology, 2009
- Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005Cancer Causes & Control, 2009
- Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesotheliomaEuropean Journal of Surgical Oncology, 2006
- Minilaparoscopy in the diagnosis of peritoneal tumor spread: prospective controlled comparison with computed tomographySurgical Endoscopy, 2004